Esophageal Cancer clinical trials
128 active trials name this condition (recorded in the registry as “Esophageal Carcinoma”) . Describe your situation to see which ones look like a fit.
Refine by biomarker
By location
- Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy
- 18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
- Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
- Minimally Invasive Esophagectomy Pain Control Trial
- Proton Therapy for Esophageal Cancer
- PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
- Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
- A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
- Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
- sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
- Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
- Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
- CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
- A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy
- BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
- A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
- A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- A Study of VET3-TGI in Patients With Solid Tumors
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- HEARTS Trial for Thoracic Cancers
- Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
- Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
- A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Hepatopancreaticobiliary and Foregut Operations for Benign and Malignant Disease
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Brodalumab in the Treatment of Immune-Related Adverse Events
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
- IDOV-Immune for Advanced Solid Tumors
- S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- Lead-212 PSV359 Therapy for Patients With Solid Tumors
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)
- A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
- CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
- Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Esophageal Carcinoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.